The 50th Anniversary of the Kefauver-Harris Amendments: Efficacy Assessment and the Randomized Clinical Trial

Journal of Clinical Hypertension

Volumn 14, Issue 11, 2012, Pages 810-815

  Turner, J Rick ^a  

^a IQVIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; STREPTOMYCIN;

AWARENESS; BIOLOGICAL ACTIVITY; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL RESEARCH; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EDITORIAL; ELIXIR; EVIDENCE BASED MEDICINE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; LUNG TUBERCULOSIS; META ANALYSIS (TOPIC); PHARMACOEPIDEMIOLOGY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT PLANNING;

HISTORY, 20TH CENTURY; HUMANS; LEGISLATION, DRUG; META-ANALYSIS AS TOPIC; PHARMACOEPIDEMIOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TERATOGENS; THALIDOMIDE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84868518593     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/jch.12012     Document Type: Editorial

References (35)

1. Johnson JA. Advancing management of hypertension through pharmacogenomics. Ann Med. 2012;44(suppl 1):S17-S22.
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
3. National Library of Medicine. Dr Frances Kathleen Oldham Kelsey. http://www.nlm.nih.gov/changingthefaceofmedicine/physicians/biography_182.html. Accessed July 26, 2012.
4. Derenzo D, Moss J. Writing Clinical Research Protocols: Ethical Perspectives. San Diego: Elsevier; 2006.
5. Turner JR. New Drug Development: An Introduction to Clinical Trials, 2nd edn. New York: Springer; 2010.
6. Turner JR. Editor's commentary: ethics in clinical research. Drug Inform J. 2012;46:155-157.
7. US Department of Health & Human Services Web site. http://www.hhs.gov/ohrp/humansubjects/guidance/belmont.html. Accessed July 26, 2012.
8. Primrose SB, Twyman RM. Principles of Gene Manipulation and Genomics. Malden, MA: Blackwell Publishing; 2006.
9. Encyclopedia Britannica web site. http://www.britannica.com/EBchecked/topic/208658/Sir-Ronald-Aylmer-Fisher. Accessed July 26, 2012.
10. Fisher RA. Statistical Methods and Scientific Inference. Oxford, UK: Hafner Publications Co.; 1956.
11. Fisher RA. The arrangement of field experiments. J Ministry Agriculture. 1926;33:503-513.
12. Fisher RA. Expansion of statistics. Am Sci. 1954;42:275-82.
13. Turner JR. Key Statistical Concepts in Clinical Trials for Pharma. New York: Springer; 2012.
14. Durham TA, Turner JR. Introduction to Statistics in Pharmaceutical Clinical Trials. London: Pharmaceutical Press; 2008.
15. Meier P. Statistics and medical experimentation. Biometrics. 1975;31:511-529.
16. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 1987;317:141-145.
17. Avorn J. In defense of pharmacoepidemiology: embracing the yin and yang of drug development. N Engl J Med. 2007;357:2219-2221.
18. Turner JR. Editor's commentary. Drug Inform J. 2011;45:687-689.
19. Matthews JNS. Introduction to Randomized Controlled Clinical Trials. London: Edward Arnold; 1999.
20. MRC Streptomycin in Tuberculosis Trials Committee. Streptomycin treatment of pulmonary tuberculosis. Br Med J. 1948;2:769-783.
21. Yoshioka A. Use of randomisation in the Medical Research Council's clinical trial of streptomycin in pulmonary tuberculosis in the 1940s. Br Med J. 1998;317:1220-1223.
22. Lienhardt C, Raviglione M, Spigelman M, et al. New drugs for the treatment of tuberculosis: needs, challenges, promise, and prospects for the future. J Infect Dis. 2012;205(suppl 2):S241-249.
23. Phillips PP, Gillespie SH, Boeree M, et al. Innovative trial designs are practical solutions for improving the treatment of tuberculosis. J Infect Dis. 2012;205(suppl 2):S250-257.
24. Cook TD, DeMets DL. Introduction to Statistical Methods for Clinical Trials. Boca Raton, FL: Chapman & Hall/CRC; 2008.
25. The coronary drug project research group. Clofibrate and niacin in coronary heart disease. JAMA. 1975;231:360-381.
26. Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol. 1986;8:1245-1255.
27. Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. Hypertension Detection and Follow-up Program Cooperative Group. JAMA. 1982;247:633-638.
28. The coronary primary prevention trial: design and implementation: the Lipid Research Clinics Program. J Chronic Dis. 1979;32:609-631.
29. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
30. Rader DJ. Editorial. Illuminating HDL - is it still a viable therapeutic target? N Engl J Med. 2007;357:2180-2183.
31. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med. 2007;357:2109-2122.
32. Turner JR, Durham TA. Integrated Cardiac Safety: Assessment Methodologies for Noncardiac Drugs in Discovery, Development, and Postmarketing Surveillance. Hoboken, NJ: Wiley; 2009.
33. Kay R. Statistical Thinking for Non-Statisticians in Drug Regulation. Chichester, UK: Wiley; 2007.
34. Turner JR. Editor's commentary: meta-methodology. Drug Inform J. 2011;45:405-411.
35. Katz DL. Clinical Epidemiology & Evidence-Based Medicine: Fundamental Principles of Clinical Reasoning & Research. Thousand Oaks, CA: Sage Publications; 2001.